A detailed history of China Universal Asset Management Co., Ltd. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 12,388 shares of NRIX stock, worth $242,433. This represents 0.03% of its overall portfolio holdings.

Number of Shares
12,388
Previous 6,969 77.76%
Holding current value
$242,433
Previous $145,000 91.72%
% of portfolio
0.03%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$18.93 - $25.69 $102,581 - $139,214
5,419 Added 77.76%
12,388 $278,000
Q2 2024

Jul 19, 2024

SELL
$12.02 - $21.3 $29,268 - $51,865
-2,435 Reduced 25.89%
6,969 $145,000
Q1 2024

Apr 29, 2024

BUY
$7.77 - $15.66 $29,471 - $59,398
3,793 Added 67.6%
9,404 $138,000
Q4 2023

May 21, 2024

SELL
$4.25 - $10.71 $16,120 - $40,623
-3,793 Reduced 40.33%
5,611 $57,000
Q4 2023

Jan 23, 2024

BUY
$4.25 - $10.71 $18,559 - $46,770
4,367 Added 351.05%
5,611 $58,000
Q3 2023

May 21, 2024

BUY
$7.86 - $10.08 $4,888 - $6,269
622 Added 100.0%
1,244 $9,000
Q3 2023

Oct 30, 2023

BUY
$7.86 - $10.08 $4,888 - $6,269
622 Added 100.0%
1,244 $10,000
Q2 2023

May 21, 2024

SELL
$8.7 - $13.28 $165 - $252
-19 Reduced 2.96%
622 $6,000
Q2 2023

Jul 27, 2023

SELL
$8.7 - $13.28 $165 - $252
-19 Reduced 2.96%
622 $6,000
Q1 2023

May 21, 2024

BUY
$8.56 - $13.26 $1,386 - $2,148
162 Added 33.82%
641 $5,000
Q1 2023

Apr 27, 2023

BUY
$8.56 - $13.26 $1,386 - $2,148
162 Added 33.82%
641 $6,000
Q4 2022

May 21, 2024

SELL
$9.86 - $14.59 $88,000 - $130,215
-8,925 Reduced 94.91%
479 $5,000
Q4 2022

Jan 31, 2023

BUY
$9.86 - $14.59 $384 - $569
39 Added 8.86%
479 $5,000
Q3 2022

Oct 21, 2022

BUY
$12.33 - $19.81 $5,425 - $8,716
440 New
440 $6,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $923M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.